An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
NCT ID: NCT04180930
Last Updated: 2025-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
950 participants
OBSERVATIONAL
2019-04-15
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post-Traumatic Stress Disorder (PTSD) Symptom Study
NCT00018798
Development and Validation of a PTSD-Related Functional Impairment Scale
NCT00651872
Post Traumatic Stress Disorder (PTSD) Hyperarousal Symptoms Treated With Physiological Stress Management
NCT00855816
Enhancing Equitable and Effective (E-3) Post Traumatic Stress Disorder (PTSD) Disability Assessment
NCT00699660
Improving Psychosocial Functioning in Older Veterans With PTSD
NCT02803125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be 950 males and females recruited from the Cincinnati VA Medical Center (Cincinnati, OH), Trauma Recovery Center, and Tripler Army Medical Center (Honolulu, HI).
the investigators anticipate that understanding the validity and reliability of the PSSI-5 and the CAPS-5 and the biomarkers related to PTSD will provide necessary information for care provided to active duty military and veterans suffering from PTSD. It will also directly inform trial designs and increase the likelihood of technical and regulatory success for new treatments for PTSD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Individuals randomized to Cohort 1 will be assigned to the CAPS-5 and will complete between two and seven research visits. Participants will be administered the CAPS-5 during visit 2, and then will be randomized a second time into groups 1-A and 1-B. Group 1-A will end participation after visit 2. Group 1-B will complete visits 3-7 and will be administered the CAPS-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
CAPS-5
Clinician Administered PTSD Scale for DMS-5
Cohort 2
Individuals randomized to Cohort 2 will be assigned to the PSSI-5 and will complete between two and seven research visits. Participants will be administered the PSSI-5 during visit 2, and then will be randomized a second time into groups 2-A and 2-B. Group 2-A will end participation after visit 2. Group 2-B will complete visits 3-7 and will be administered the PSSI-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
PSSI-5
PTSD Symptom Scale Interview for DSM-5
Cohort 3
Individuals randomized to Cohort 3 will have three office visits and will complete the CAPS-5 and the PSSI-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
CAPS-5
Clinician Administered PTSD Scale for DMS-5
PSSI-5
PTSD Symptom Scale Interview for DSM-5
Cohort 4
Individuals randomized to Cohort 4 will have three office visits and will complete the CAPS-IV and the CAPS-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
CAPS-5
Clinician Administered PTSD Scale for DMS-5
CAPS-IV
Clinician Administered PTSD Scale for DSM-IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CAPS-5
Clinician Administered PTSD Scale for DMS-5
PSSI-5
PTSD Symptom Scale Interview for DSM-5
CAPS-IV
Clinician Administered PTSD Scale for DSM-IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Competent to give informed consent
* Have experienced any Criterion A qualifying traumatic event as defined by the Life Events Checklist for DSM-5 (LEC-5)
* Score a 3 or above on the Primary Care-Post Traumatic Stress Disorder Screen (PC-PTSD-5)
Exclusion Criteria
* Assessment using CAPS or PSSI in the previous 1 year
* Currently receiving psychotherapy or counseling for PTSD
* Moderate to sever cognitive impairment as measured by the Montreal Cognitive Assessment (MoCA)
* Meet criteria for unmedicated Bipolar I, Bipolar II, Schizophrenia, or other psychotic disorders in the last month
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
U.S. Army Medical Research and Development Command
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kathleen M Chard, PhD
Role: PRINCIPAL_INVESTIGATOR
Cincinnati VA Medical Center, University of Cincinnati
Brian Marx, PhD
Role: PRINCIPAL_INVESTIGATOR
National Center for PTSD at VA Boston Healthcare System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tripler Army Medical Center
Honolulu, Hawaii, United States
Cincinnati VA Medical Center - Trauma Recovery Center
Fort Thomas, Kentucky, United States
Walter Reed National Military Medical Center
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-7745
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.